Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Active Psoriatic Arthritis (Discover-1)
NCT03162796Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: American College of Rheumatology 20 Response at 24 weeks. Started Aug 2017; status: completed.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03162796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162796.